Title Category Credit Event date Cost
Achieving Value-Based Care: The Role of Oncology Clinical Pathways
  • Oncology
  • AAPC
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
05/20/2021 $0.00 Activity descriptionOncology clinical pathways are defined by the American Society of Clinical Oncology (ASCO) as detailed, evidence-based treatment protocols for specific disease types and stages that deliver high-quality cancer care. With the rapid approval of new anticancer therapies, along with the rising cost of cancer care, pathways serve a critical role in the delivery of high-quality and high-value cancer treatments while reducing unwarranted variation in care.
Update in the Utilization of Blood/Marrow Transplant and Emerging Diagnoses on the Horizon
  • Disease Management
  • Oncology
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • APA
  • Attendance
  • CCMC - General
  • ASWB
$0.00 Activity descriptionThis activity consists of recorded presentations from the 28th Annual National Conference held in Minneapolis, Minn., on Oct. 14, 2019.
The Case for Community-based, High-Risk Women’s Cancer Programs
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • APA
  • Attendance
  • CCMC - General
  • ASWB
$0.00 Activity descriptionThis activity consists of recorded presentations from the 28th Annual National Conference held in Minneapolis, Minn., on Oct. 14, 2019.
The CAR T-cell Therapy Tsunami: Emerging Therapies and Barriers to Access
  • Disease Management
  • Oncology
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • APA
  • Attendance
  • CCMC - General
  • ASWB
$0.00 Activity descriptionThis activity consists of recorded presentations from the 28th Annual National Conference held in Minneapolis, Minn., on Oct. 15, 2019.Chimeric antigen receptor (CAR) T-cell therapy has the potential to revolutionize cancer treatment. This therapy is expected to expand quickly with the number of clinical trials increasing by 113 percent over the last year! This session will explore the complexities of CAR T-cell therapy, explain how it works, and discuss the future applications we may expect to see in this field.
Cancer Survivorship: A Personalized Precision Approach
  • Disease Management
  • Oncology
  • Transplantation
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • APA
  • Attendance
  • CCMC - General
  • ASWB
$0.00 Activity descriptionThis activity consists of recorded presentations from the 28th Annual National Conference held in Minneapolis, Minn., on Oct. 16, 2019.
Value in Cancer Care: Finding the Path to Progress
  • Disease Management
  • Managed care
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • APA
  • Attendance
  • CCMC - General
  • ASWB
$0.00 Activity descriptionThis activity consists of recorded presentations from the 28th Annual National Conference held in Minneapolis, Minn., on Oct. 15, 2019.The cost of cancer care in the U.S. has increased dramatically over the last three decades. Among factors contributing to this huge increase are rising cancer prevalence, due in part to our aging population, and the rapidly increasing cost of pharmaceuticals and other interventions. Mounting physician fees and cost-sharing on the part of the insurance industry have also made a significant contribution.
Non-HLA Barriers to Blood/Marrow Transplant
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - Ethics
$0.00 Activity descriptionHistorically, the lack of finding a human leukocyte antigens (HLA)-match has been perceived as the largest barrier to BMT. Many barriers besides a lack of suitably matched donors exist and can have an adverse impact on access and outcomes of BMT. This session will identify key barriers to BMT including barriers that prevent access to care, such as language and cultural differences; illiteracy; and environmental, geographic, genetic, and medical barriers.
Acute Myelogenous Leukemia: New Therapies after 40 Years!
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionAML is one of the most aggressive cancers. While other cancers have benefited from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. With improved biologic understanding of AML and the incorporation of genetic prognostic markers and novel therapeutic options bringing new advancements to the field, individuals with AML have reason to hope. This session will review recent advances and new agents that have been approved for the treatment of AML and discuss the role of biomarkers in AML treatment decisions.
CAR T-cell Therapy: A Personalized Immunotherapy Approach to Cancer
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionWhile chimeric antigen receptor (CAR) T-cell therapy has proven successful in treating certain cancers, severe toxicities have limited its widespread application. This new cancer treatment approach is powerful and does come with serious risks that need to be considered before starting therapy. This session will identify the indications for CAR T-cell therapy and describe the challenges from the toxicities that are unique to CAR T cells. Toxicity management will also be discussed.
Hepatocellular Carcinoma: Treatment Options Outside of Transplant
  • Transplantation
  • Disease Management
  • Oncology
  • ACPE - Pharmacist
  • ACPE - Pharmacy Technician
  • AMA
  • ANCC
  • Attendance
  • CCMC - General
$0.00 Activity descriptionLiver transplantation (LT) is considered the best curative treatment for patients with cirrhosis and hepatocellular carcinoma (HCC) within Milan criteria. Several therapeutic procedures have been proposed as bridging treatments for individuals with HCC awaiting LT. The choice of each treatment is based on: the characteristics of the patient; liver function; comorbidities; and on the number, dimensions, and localization of HCC.

Pages